Please note: The information displayed on this page might be outdated.
Stemline Therapeutics, Inc.: ELZONRIS, a commercial targeted therapy directed to IL-3 receptor (CD123), approved for BPDCN and ongoing trials in other indications; SL-801 an oral small molecule reversible inhibitor of XPO1 in Ph 1 trial; and SL-701 an immunotherapeutic that completed Ph 2 trial in pts w/2nd line GBM
Based in...
US - Middle Atlantic
Clinical Stage
Marketed, Phase l or ll
Disease Space
Immunotherapy, Oncology, Rare Disease
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Platform Technology, Small Molecule
750 Lexington Ave
11th Floor
New York, NY 10022
United States

Top 10 Holders of Stemline Therapeutics, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Water Island Capital LLC 1.83 915,637 10.83 Funds 5/31/20
Principal Global Investors LLC 0.55 289,855 3.43 Funds 12/31/19
Apo Asset Management GmbH 0.54 272,079 3.22 Funds 3/31/20
LSP Advisory BV 0.24 124,600 1.47 Funds 10/31/19
The Vanguard Group, Inc. 0.20 100,916 1.19 Funds 3/31/20
SSgA Funds Management, Inc. 0.11 56,858 0.67 Funds 3/31/20
Riverbridge Partners LLC 0.07 34,822 0.41 Funds 4/30/20
Goldman Sachs Asset Management International 0.07 33,660 0.40 Funds 5/31/20
Russell Investment Management LLC 0.05 23,786 0.28 Funds 3/31/20
Sparrow Capital Management, Inc. 0.04 18,430 0.22 Funds 5/29/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.